A108 USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY

BACKGROUND: Ustekinumab is a monoclonal antibody targeting the p40 subunit of interleukins 12 and 23. Gastroenterologists have begun to prescribe ustekinumab off-label for treatment of Crohn’s disease (CD) due to promising clinical trials but robust open label data is lacking AIMS: Assess the real-w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Can Assoc Gastroenterol
Main Authors: Ma, C, Fedorak, R, Kaplan, G G, Dieleman, L A, Devlin, S, Stern, N, Kroeker, K I, Seow, C, Leung, Y, Novak, K L, Halloran, B P, Huang, V, Wong, K, Ghosh, S, Panaccione, R
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Poster Presentations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507693/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.109
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki